BioSpace News Archive

In the trial, 396 patients with moderate-to-severe psychotic symptoms related to adult schizophrenia received either Nuplazid or placebo added to their current antipsychotic treatment. The patients receiving Nuplazid showed a consistent trend in symptom improvement but did not hit statistical significance on the primary endpoint.

Research recently published by researchers from The Scripps Research Institute in the Proceedings of the National Academy of Sciences found that exosomes play an integral role in the development of neurons and neural circuits. In addition, they are able to fix brain cells damaged by developmental disease.

With the positive results from this trial, as well as an earlier Phase III trial, Myovant Sciences plans to seek regulatory approval later this year.

If you are feeling undervalued at work, it’s productive to think about how you’ve demonstrated your value internally. Here are four ways to demonstrate your worth in the workplace!

Researchers with the Weizmann Institute of Science worked with mice with an ALS-like disease. They found that the course of the disease slowed after the mice received specific strains of gut microbes or substances that were secreted by the microbes. The results suggest that the microbiome may play a regulatory role in people with ALS.

“Our ultimate goal is to provide a solution to an organ shortage that causes an average of 20 people per day in the U.S. alone to die waiting for an organ transplant,” quoted Rich Boling, the vice-president of corporate advancement at Techshot.

The Fortune 500 list is compiled of the 500 U.S.-based companies that generate the most revenue. In the latest ranking, one dozen biopharma companies were included, with one, Johnson & Johnson, breaking into the top 50 and only four in the top 100.

Testing for genetic weaknesses in repairing DNA could pick out men who may benefit from a new type of targeted nuclear medicine, a new study reports.

HERA-GITRL Shows Strong Single-Agent Anti-Tumor Activity in Vitro and in Vivo and is Superior to Bivalent Clinical Benchmark Antibody

The academic hematology department of Erasmus Medical Center is globally the first hospital to offer every multiple myeloma patient an innovative diagnostic service that predicts the aggressiveness of the disease by measuring 92 genes in the cancer cells